Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALNY Alnylam Pharmaceuticals

Closed President's Day 02-13 16:00:00 EST

314.40

+5.92

+1.92%

盘后314.40

+0.000.00%

19:42 EST

High318.44	Low302.55	Vol1.48M
Open302.55	D1 Closing308.48	Amplitude5.15%
Mkt Cap41.54B	Tradable Cap39.66B	Total Shares132.11M
T/O461.53M	T/O Rate1.17%	Tradable Shares126.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALNY","market":"US","secType":"STK","nameCN":"Alnylam Pharmaceuticals","latestPrice":314.4,"timestamp":1771016400000,"preClose":308.48,"halted":0,"volume":1476326,"hourTrading":{"tag":"盘后","latestPrice":314.4,"preClose":314.4,"latestTime":"19:42 EST","volume":188054,"amount":59173869.1288,"timestamp":1771029766017,"change":0,"changeRate":0,"amplitude":0.007952},"delay":0,"changeRate":0.01919087136929447,"floatShares":126154848,"shares":132113818,"eps":2.33,"marketStatus":"Closed President's Day","change":5.92,"latestTime":"02-13 16:00:00 EST","open":302.55,"high":318.44,"low":302.55,"amount":461528930.77718,"amplitude":0.051511,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.33,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":308.48,"preHourTrading":{"tag":"盘前","latestPrice":302.08,"preClose":308.48,"latestTime":"09:29 EST","volume":469,"amount":142870.49917,"timestamp":1770992999999,"change":-6.4,"changeRate":-0.020747,"amplitude":0.021395},"postHourTrading":{"tag":"盘后","latestPrice":314.4,"preClose":314.4,"latestTime":"19:42 EST","volume":188054,"amount":59173869.1288,"timestamp":1771029766017,"change":0,"changeRate":0,"amplitude":0.007952},"volumeRatio":0.801007903646627,"impliedVol":0.4146,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/ALNY","defaultTab":"news","newsList":[{"id":"2611123124","title":"Cantor Fitzgerald Sticks to Their Hold Rating for Alnylam Pharma (ALNY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611123124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611123124?lang=en_us&edition=fundamental","pubTime":"2026-02-15 20:15","pubTimestamp":1771157749,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Olivia Brayer maintained a Hold rating on Alnylam Pharma on February 12 and set a price target of $400.00. The company’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-hold-rating-for-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-their-hold-rating-for-alnylam-pharma-alny-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2611144781","title":"Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2611144781","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611144781?lang=en_us&edition=fundamental","pubTime":"2026-02-15 06:22","pubTimestamp":1771107742,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) books FY 2025 profit as quarterly revenue tops US$1 billion\nAlnylam Pharmaceuticals (ALNY) has capped FY 2025 with fourth quarter revenue of US$1,097.0 million and basic EPS of US$1.41, alongside net income of US$186.4 million that continues the company’s recent move into profitability. The company has seen revenue step up from US$593.2 million and basic EPS of US$0.65 loss in Q4 2024 to US$594.2 million with EPS of US$0.44 loss in Q1 2025, US$773.7 million with...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-turns-profitable-with-q4-eps-of","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/alnylam-pharmaceuticals-alny-turns-profitable-with-q4-eps-of","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2611169354","title":"Alnylam price target lowered to $360 from $408 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2611169354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611169354?lang=en_us&edition=fundamental","pubTime":"2026-02-13 23:45","pubTimestamp":1770997535,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $360 from $408 and keeps an Equal Weight rating on the shares. Q4 revenue was p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-360-from-408-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-360-from-408-at-morgan-stanley-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","LU1989772923.USD","LU0106261372.USD","LU2271345857.HKD","LU1244550221.USD","BK4581","LU1732799900.SGD","BK4516","LU1791710400.SGD","ALNY","BK4127","LU0528227936.USD","LU1791710582.SGD","LU2089284900.SGD","LU2089283258.USD","LU0882574055.USD","LU0889565916.HKD","LU1244550494.USD","BK4504","LU0795875086.SGD","LU1732800096.USD","BK4585","LU2133065610.SGD","LU0006306889.USD","BK4534","LU0795875169.SGD","LU0320765646.SGD","LU0114720955.EUR","LU0106831901.USD","LU1363072403.SGD","LU0320765992.SGD","LU0882574139.USD","LU2347655156.SGD","LU0098860793.USD","LU1720051017.SGD","LU0557290698.USD","LU1074936037.SGD","LU2111349929.HKD","LU2028103732.USD","LU0158827948.USD","LU1244550577.SGD","LU0234570918.USD","LU1989772840.SGD","LU0225283273.USD","IE00BKVL7J92.USD","LU1548497426.USD","LU0314104364.USD","BK4588","LU1162221912.USD","LU1720051108.HKD"],"gpt_icon":0},{"id":"2611152231","title":"RBC Lowers Price Target on Alnylam Pharmaceuticals to $450 From $465, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611152231","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611152231?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:02","pubTimestamp":1770987750,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) has an average rating of overweight and mean price target of $467.09, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALNY"],"gpt_icon":0},{"id":"2611154661","title":"Alnylam Pharmaceuticals Inc : Raymond James Cuts Target Price to $420 From $472","url":"https://stock-news.laohu8.com/highlight/detail?id=2611154661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611154661?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:31","pubTimestamp":1770985883,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z919G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","ALNY","BK4139","LU0889565916.HKD","LU0114720955.EUR","LU0882574055.USD","BK4548","BK4585","LU0320765992.SGD","BK4588"],"gpt_icon":0},{"id":"2611138644","title":"U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections","url":"https://stock-news.laohu8.com/highlight/detail?id=2611138644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611138644?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:43","pubTimestamp":1770965029,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, Humana, Waste Connections Feb 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nL4N3Z90HT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COIN","COHR","AVNT","CRSR","ECL","BFAM","ADI","COR","CONL","CW","BBIO","AMAT","BROS","ALNY","TXG","ALB","APPX","CLYM","CONY","AEE","COIG","CBRE","CROX","DKNG","AMG","BRKR","DAR","DBD","EXC","ANET","COIA","ABNB","LU1861215975.USD","BIO","CONI","AEP","CGNX","EEFT","FIAT","ETR","BAX","COYY","AGIO","DLTR","CONX","COIW","DXCM","BDC","APP","COIO"],"gpt_icon":1},{"id":"2611985187","title":"Alnylam Pharmaceuticals Inc : Chardan Capital Markets Cuts Target Price to $425 From $475","url":"https://stock-news.laohu8.com/highlight/detail?id=2611985187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611985187?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:22","pubTimestamp":1770963742,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z909O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","LU0882574055.USD","BK4585","BK4588","LU0109394709.USD","LU0320765992.SGD","ALNY","BK4139","LU0114720955.EUR","LU0889565916.HKD"],"gpt_icon":0},{"id":"2611987187","title":"Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2611987187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611987187?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:03","pubTimestamp":1770962584,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the International Operations category. Alnylam Pharmaceuticals faces material execution...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/execution-risks-loom-as-alnylam-races-to-scale-global-operations-for-amvuttra-and-2030-growth-ambitions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/execution-risks-loom-as-alnylam-races-to-scale-global-operations-for-amvuttra-and-2030-growth-ambitions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0114720955.EUR","BK4585","LU0320765992.SGD","LU0109394709.USD","BK4588","LU0882574055.USD","ALNY","LU0889565916.HKD","BK4139","BK4548"],"gpt_icon":0},{"id":"2611182196","title":"Alnylam Pharmaceuticals: Amvuttra-Driven Profitability Inflection Supports Long-Term Growth and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2611182196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611182196?lang=en_us&edition=fundamental","pubTime":"2026-02-13 13:55","pubTimestamp":1770962119,"startTime":"0","endTime":"0","summary":"Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alnylam-pharmaceuticals-amvuttra-driven-profitability-inflection-supports-long-term-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alnylam-pharmaceuticals-amvuttra-driven-profitability-inflection-supports-long-term-growth-and-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY"],"gpt_icon":0},{"id":"2611381904","title":"Alnylam Pharmaceuticals Projects Powerful Growth After Breakout Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2611381904","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611381904?lang=en_us&edition=fundamental","pubTime":"2026-02-13 08:18","pubTimestamp":1770941896,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (($ALNY)) has held its Q4 earnings call. Read on for the main highlights of the call. Alnylam Pharmaceuticals’ latest earni...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alnylam-pharmaceuticals-projects-powerful-growth-after-breakout-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alnylam-pharmaceuticals-projects-powerful-growth-after-breakout-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4588","LU0109394709.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","BK4139","LU0114720955.EUR","LU0320765992.SGD","ALNY"],"gpt_icon":0},{"id":"2611971174","title":"Alnylam Pharmaceuticals Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2611971174","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611971174?lang=en_us&edition=fundamental","pubTime":"2026-02-13 03:03","pubTimestamp":1770922980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2026 14:03 ET (19:03 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"1161353209","title":"Stock Track | Alnylam Pharmaceuticals Plummets 5.03% Intraday on Q4 Revenue Miss and Weak 2026 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1161353209","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161353209?lang=en_us&edition=fundamental","pubTime":"2026-02-12 22:40","pubTimestamp":1770907208,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals (ALNY) shares plummeted 5.03% during intraday trading on Thursday, following the release of the company's fourth-quarter financial results.The biopharmaceutical company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ALNY"],"gpt_icon":0},{"id":"2610192913","title":"Alnylam Q4 net product revenue misses expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2610192913","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610192913?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:07","pubTimestamp":1770901668,"startTime":"0","endTime":"0","summary":"Alnylam Q4 net product revenue misses expectationsOverviewRNAi therapeutics firm's Q4 net product revenue grew 121% yr/yr but missed expectationsAdjusted EPS for Q4 beat analyst expectationsCompany la","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z80QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","LU0320765992.SGD","LU0889565916.HKD","BK4139","LU0882574055.USD","ALNY","BK4585","LU0114720955.EUR","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2610292930","title":"BRIEF-Alnylam Pharmaceuticals Q4 Adjusted EPS USD 1.28 Vs. IBES Estimate USD 1.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2610292930","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610292930?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901247,"startTime":"0","endTime":"0","summary":"Feb 12  - Alnylam Pharmaceuticals Q4 adjusted net income USD 169.753 million.Q4 net product revenue USD 1,097.033 million vs. IBES estimate USD 1,173 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nPLXAA0C44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU0882574055.USD","ALNY","BK4585","BK4588","BK4548","BK4139"],"gpt_icon":0},{"id":"2610929817","title":"Alnylam Pharmaceuticals Q4 Net Income USD 111.543 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929817","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929817?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901203,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nPLXAA0C44:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4588","LU0109394709.USD","LU0889565916.HKD","LU0882574055.USD","BK4585","BK4139","LU0114720955.EUR","LU0320765992.SGD","ALNY"],"gpt_icon":0},{"id":"2610235929","title":"Alnylam Pharmaceuticals Inc Outlook FY Total Net Product Revenue $4,900 Mln - $5,300 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2610235929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610235929?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nPLXAA0C44:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","ALNY","LU0889565916.HKD","LU0109394709.USD","BK4588","BK4139","LU0114720955.EUR","BK4585","BK4548","LU0320765992.SGD"],"gpt_icon":0},{"id":"1190871752","title":"Earning Preview: Alnylam Pharmaceuticals revenue is expected to increase by 1.01 billion, and institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1190871752","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190871752?lang=en_us&edition=fundamental","pubTime":"2026-02-05 11:56","pubTimestamp":1770263784,"startTime":"0","endTime":"0","summary":"Abstract Alnylam Pharmaceuticals will report its quarterly earnings on February 12, 2026 Pre-Market; this preview consolidates recent financials and forecasts to frame expectations for revenue,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Alnylam Pharmaceuticals revenue is expected to increase by 1.01 billion, and institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY"],"gpt_icon":0},{"id":"2607078707","title":"Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity?","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607078707?lang=en_us&edition=fundamental","pubTime":"2026-01-31 04:31","pubTimestamp":1769805113,"startTime":"0","endTime":"0","summary":"Wondering if Alnylam Pharmaceuticals at around US$346 is offering you fair value or asking too much? This article walks through the key numbers that matter for investors focused on price versus value.\nThe stock has pulled back recently, with a 6.3% decline over the last 7 days and a 12.7% decline over the past 30 days, although the 1 year return sits at 25.1% and the 5 year return at 119.6%.\nRecent attention on Alnylam Pharmaceuticals has centred on its broader pipeline and commercial...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alny/alnylam-pharmaceuticals/news/has-the-recent-pullback-in-alnylam-pharmaceuticals-alny-open","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0109394709.USD","ALNY","BK4139","LU0889565916.HKD","LU0114720955.EUR","LU0882574055.USD","BK4548","DCF","BK4585","LU0320765992.SGD","BK4588"],"gpt_icon":0},{"id":"2607040307","title":"Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Amgen (AMGN) and Indivior (INDV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040307","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040307?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:20","pubTimestamp":1769790013,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report), Amgen (AMGN – Research R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-amgen-amgn-and-indivior-indv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-amgen-amgn-and-indivior-indv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2242646821.SGD","LU0882574055.USD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0114720955.EUR","AMGN","BK4566","LU0289739699.SGD","INDV","LU0889565916.HKD","IE00BFTCPJ56.SGD","LU2242652126.USD","LU1057294990.SGD","HCSG","LU1983299246.USD","BK4007","XBI","XLV","LU1023059063.AUD","BK4599","BK4533","BK4137","IE00B4R5TH58.HKD","LU0029874061.USD","LU1571399168.USD","BK4581","LU0320765992.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4588","LU0122379950.USD","IE0009355771.USD","LU0058720904.USD","LU2468319806.SGD","IE0002141913.USD","BK4139","ALNY","BK4534","LABU","IE00B2B36J28.USD","BK4585","SG9999001440.SGD","BK4548","LU0868494617.USD","LU2112291526.USD","LU0128526141.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2607049759","title":"Alnylam price target lowered to $462 from $529 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607049759?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:17","pubTimestamp":1769782662,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Alnylam (ALNY) to $462 from $529 and keeps a Buy rating on the shares as part of the firm’s Q4 small-to-mid...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-462-from-529-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alnylam-price-target-lowered-to-462-from-529-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALNY","BK4548","LU0114720955.EUR","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","LU0882574055.USD","BK4585","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alnylam.com","stockEarnings":[{"period":"1week","weight":-0.0419},{"period":"1month","weight":-0.143},{"period":"3month","weight":-0.3},{"period":"6month","weight":-0.2996},{"period":"1year","weight":0.1869},{"period":"ytd","weight":-0.2094}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.028609},{"month":2,"riseRate":0.454545,"avgChangeRate":0.000264},{"month":3,"riseRate":0.47619,"avgChangeRate":-0.013154},{"month":4,"riseRate":0.380952,"avgChangeRate":-0.019703},{"month":5,"riseRate":0.619048,"avgChangeRate":0.04124},{"month":6,"riseRate":0.636364,"avgChangeRate":0.064494},{"month":7,"riseRate":0.681818,"avgChangeRate":0.106925},{"month":8,"riseRate":0.590909,"avgChangeRate":0.037005},{"month":9,"riseRate":0.545455,"avgChangeRate":0.034409},{"month":10,"riseRate":0.409091,"avgChangeRate":-0.042013},{"month":11,"riseRate":0.727273,"avgChangeRate":0.078577},{"month":12,"riseRate":0.454545,"avgChangeRate":0.006257}],"exchange":"NASDAQ","name":"Alnylam Pharmaceuticals","nameEN":"Alnylam Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alnylam Pharmaceuticals,ALNY,Alnylam Pharmaceuticals股票,Alnylam Pharmaceuticals股票老虎,Alnylam Pharmaceuticals股票老虎国际,Alnylam Pharmaceuticals行情,Alnylam Pharmaceuticals股票行情,Alnylam Pharmaceuticals股价,Alnylam Pharmaceuticals股市,Alnylam Pharmaceuticals股票价格,Alnylam Pharmaceuticals股票交易,Alnylam Pharmaceuticals股票购买,Alnylam Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alnylam Pharmaceuticals(ALNY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alnylam Pharmaceuticals(ALNY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}